江西三鑫医疗科技股份有限公司可转债发行最新进展，投资者须知
【2026年5月13日】 江西三鑫医疗科技股份有限公司（以下简称“三鑫医疗”或“公司”，证券代码：300453）于今日发布公告，详细说明了其向不特定对象发行可转换公司债券（简称“可转债”）的最新进展及相关事项。以下为本次公告的要点及对投资者的重要解读：
一、发行进展及最新披露
- 三鑫医疗的可转债发行申请已于2026年4月24日获得深圳证券交易所上市审核委员会审核通过。
- 公司于2026年4月25日在中国证监会指定信息披露平台（巨潮资讯网）进行了相关公告披露。
- 因公司《2025年年度报告》和《2026年一季度报告》已于2026年4月27日公开披露，公司与相关中介机构对募集说明书等申请文件的部分内容进行了补充、更新和修订。
- 更新后的《募集说明书（注册稿）》及相关文件已于2026年5月13日在巨潮资讯网披露，投资者可查阅详细内容。
二、对股东和投资者的潜在影响及风险提示
- 关键影响： 可转债发行若顺利注册并实施，预计将为公司带来新的融资，有助于优化资本结构、增强资金实力，支持公司未来发展及战略实施，可能对公司股价产生正面影响。
- 不确定性风险： 目前该事项尚需履行中国证监会的注册程序，最终能否获得证监会同意注册的批复及其时间尚存不确定性。相关决定将对公司后续资金状况及市场表现产生明显影响。
- 公司承诺在收到中国证监会作出的注册决定文件后，将第一时间公告，敬请投资者密切关注后续进展并注意投资风险。
三、投资者建议
- 关注公司在巨潮资讯网等官方平台的后续公告，及时获取可转债发行注册进展信息。
- 评估可转债发行对公司财务状况及未来成长性的潜在影响，把握投资机会，同时警惕注册不确定性带来的风险波动。
免责声明
本报道内容基于公司公告资料整理，仅供投资者参考，不构成任何投资建议。投资者据此操作，风险自负。请密切关注公司及监管机构后续公告，理性决策。
English Version
Key Developments in Jiangxi Sanxin Medical’s Convertible Bond Issuance: Information for Investors
[May 13, 2026] Jiangxi Sanxin Medical Technology Co., Ltd. (hereinafter “Sanxin Medical” or “the Company”, stock code: 300453) has released an important announcement updating the market on the latest progress regarding its planned issuance of convertible corporate bonds to unspecified investors. Below are the highlights and implications for shareholders:
1. Progress Update and Recent Disclosures
- Sanxin Medical’s application to issue convertible bonds was approved by the Listing Review Committee of the Shenzhen Stock Exchange on April 24, 2026.
- Relevant announcements were published on April 25, 2026, via the official disclosure platform (cninfo.com.cn) designated by the China Securities Regulatory Commission (CSRC).
- Following the public disclosure of the Company’s 2025 annual report and Q1 2026 report on April 27, 2026, Sanxin Medical and relevant intermediaries have supplemented, updated, and revised parts of the prospectus and application documents accordingly.
- The updated “Prospectus (Registration Draft)” and related documents were published on May 13, 2026, and are available for investor review on cninfo.com.cn.
2. Key Implications and Risks for Shareholders
- Potential Impact: If the convertible bond issuance is successfully registered and completed, the Company expects an influx of new funds, enhancing its capital structure and supporting future growth and strategic initiatives—potentially having a positive impact on the share price.
- Uncertainty Risk: The issuance still requires registration with the CSRC, and there is uncertainty regarding whether and when this approval will be granted. The outcome could significantly affect the Company’s financial position and market performance.
- The Company will promptly announce the CSRC’s decision once received. Investors should closely monitor these updates and remain aware of associated investment risks.
3. Investor Recommendations
- Keep track of further announcements on cninfo.com.cn and other official channels to stay informed about registration progress.
- Evaluate the potential impact of the convertible bond issuance on the Company’s financial health and long-term growth prospects, while being cautious of volatility tied to registration uncertainty.
Disclaimer
This report is based on official company disclosures and is provided for informational purposes only. It does not constitute investment advice. Investors should make rational decisions and bear their own risk, paying close attention to subsequent announcements from the Company and regulatory authorities.
